Neutrophil viability in surgical patients and its relationship with neutrophil functionality

Neutrophil viability in surgical patients and its relationship with neutrophil functionality - Neutrophil viability study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49355

Enrollment

Registered

2019-02-13

Start date

2017-10-31

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

death of white blood cells neutrophil cell death

Interventions

leukocyte

neutrophil

neutrophil viability

surgery

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: leukocyte viability factor * 0.95

Exclusion criteria

Exclusion criteria: Immunosuppressive drugs (e.g. chemotoxic and cytostatic drugs) or positive HIV-status or use of clozapine medication

Design outcomes

Primary

Measure	Time frame
The primary endpoint is neutrophil cell death, determined by double staining of Annexin V and PI. This will be compared to the decreased viability factor of the initial routine blood sample to validate the viability factor.	—

Secondary

Measure	Time frame
Secondary endpoints are neutrophil phagocytosis and responsiveness to fMLP.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)